Perceptive Advisors LLC boosted its holdings in Oncomed Pharmaceuticals Inc (NASDAQ:OMED) by 152.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,620,897 shares of the biopharmaceutical company’s stock after purchasing an additional 1,582,608 shares during the quarter. Perceptive Advisors LLC owned approximately 6.92% of Oncomed Pharmaceuticals worth $10,745,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also added to or reduced their stakes in OMED. BlueCrest Capital Management Ltd acquired a new position in Oncomed Pharmaceuticals in the fourth quarter valued at $133,000. Virtu Financial LLC acquired a new position in Oncomed Pharmaceuticals in the fourth quarter valued at $170,000. Goldman Sachs Group Inc. increased its stake in Oncomed Pharmaceuticals by 89.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 52,106 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 24,653 shares during the last quarter. Spark Investment Management LLC acquired a new position in Oncomed Pharmaceuticals in the fourth quarter valued at $228,000. Finally, Two Sigma Investments LP increased its stake in Oncomed Pharmaceuticals by 154.0% in the fourth quarter. Two Sigma Investments LP now owns 61,365 shares of the biopharmaceutical company’s stock valued at $252,000 after purchasing an additional 37,205 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.
Shares of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) opened at $3.29 on Monday. Oncomed Pharmaceuticals Inc has a 1 year low of $1.74 and a 1 year high of $10.42.
Several equities analysts recently commented on OMED shares. Zacks Investment Research lowered Oncomed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 6th. HC Wainwright reiterated a “hold” rating and issued a $3.00 target price on shares of Oncomed Pharmaceuticals in a research note on Friday. Finally, Cantor Fitzgerald set a $6.00 target price on Oncomed Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, January 4th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $5.44.
About Oncomed Pharmaceuticals
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Want to see what other hedge funds are holding OMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oncomed Pharmaceuticals Inc (NASDAQ:OMED).
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.